Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.
BACKGROUND
In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated.


METHODS
Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated.


CONCLUSIONS
No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid.
Atahan
Lale
L
Department of Radiation Oncology, Hacettepe University, Ankara 06100, Turkey.
Yildiz
Ferah
F
Cengiz
Mustafa
M
Kaplan
Bunyamin
B
Ozkan
Metin
M
Yazici
Gozde
G
Gündoğ
Mete
M
Haydaroğlu
Ayfer
A
Korcum
Aylin F
AF
Sengöz
Meriç
M
Dinçer
Maktav
M
Akmansu
Müge
M
Engin
Kayihan
K
Hayran
Mutlu
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D010147:Pain Measurement; D010166:Palliative Care; D011879:Radiotherapy Dosage; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid